Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Extra-corporeal CO2 Removal as an Adjunct to Non-Invasive Ventilation in Acute Severe Exacerbations of COPD
Verified date | August 2021 |
Source | Guy's and St Thomas' NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic obstructive pulmonary disease (COPD) is one of the UKs commonest chronic diseases and is responsible for a significant number of acute hospital admissions. COPD is characterised by progressive destruction in the elastic tissue within the lung, causing respiratory failure. The clinical course of COPD is characterised by recurrent acute exacerbations (AECOPD), causing considerable morbidity and mortality. Patients with moderate to severe acute exacerbations present with increased work of breathing and hypercapnia. The standard for respiratory support in this setting is non-invasive ventilation (NIV), a management strategy underpinned by a considerable evidence base. However despite NIV, up to 30% of patients with AECOPD will 'fail' and require intubation and mechanical ventilation. The mortality rate for patients requiring NIV is approximately 4%, if conversion to mechanical ventilation occurs the mortality is 29%. The last decade has seen an increasing interest in the provision of extracorporeal support for respiratory failure. The key element that has underpinned improving survival has been technological advancement. This has resulted in pumps causing less blood trauma and inflammatory response, better percutaneous cannulation techniques and coated circuits with reduced heparin requirements. Overall this has significantly reduced the complications associated with the provision of extracorporeal support. One variation of this technique (extra-corporeal CO2 removal ECCO2R) allows CO2 clearance from the blood. This approach has been the subject of a number of animal experiments and uncontrolled human case series demonstrating improved arterial CO2 and reduced work of breathing. Our own unpublished series demonstrates the same physiological changes. However to date the benefits of this approach have not been tested in a randomised controlled trial. The hypothesis is that the addition of ECCO2R to NIV will shorten the duration of NIV and reduce likelihood of intubation.
Status | Completed |
Enrollment | 21 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria - Known COPD with an acute exacerbation. An acute exacerbation is defined as per the GOLD criteria as an increase in dyspnoea, cough and/or sputum over the patient's normal symptoms. A severe exacerbation is defined as one requiring hospital admission. - Patients with a persistent arterial pH<7.30 due primarily to hypercapnic respiratory failure after standard medical therapy and at least 1 hour of NIV. - Age over 18 Exclusion Criteria - Haemodynamic instability after ensuring euvolaemia - Acute multiple organ failure requiring other organ supportive therapy, including indication for intubation and mechanical ventilation - Known allergy/intolerance of heparin including known heparin induced thrombosis and thrombocytopaenia - Acute uncontrolled haemorrhage - Intracerebral haemorrhage - Recent (<6 months) ischaemic cerebrovascular accident - Organ transplant recipient - Expected to die within 24 hours - Venous abnormality or body habitus precluding cannulation - Contraindication to NIV (as per British Thoracic Society recommendation) - Facial burns/trauma/recent facial or upper airway surgery - Vomiting - Fixed upper airway obstruction - Undrained pneumothorax - Recent upper gastrointestinal surgery - Inability to protect the airway - Life threatening hypoxaemia (PaO2/FiO2 <20kPa) - Bowel obstruction - Patient refusal - Pregnancy - Severe hepatic failure (ascites, hepatic encephalopathy or bilirubin >100umol/L) - Severe chronic cardiac failure (NYHA class III or IV) - Bleeding diathesis (INR>1.5, platelets <80,000) in the absence of anticoagulation therapy |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guy's and St Thomas' NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
Guy's and St Thomas' NHS Foundation Trust | Alung Technologies |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to cessation NIV | Time to cessation of NIV is defined as from NIV commencement to 6 hours without NIV. | participants will be followed for the duration of ICU stay, an expected average of 4 days | |
Secondary | Mortality | at 90 days | ||
Secondary | Time to event analysis | This is a composite endpoint to assess the ability to complete the required elements of the study from screening to commencement of ECCO2R in a clinically relevant timeframe | initial phase of study, an expected average of 3 hours | |
Secondary | Health-related quality of life (HRQoL) | 90 days | ||
Secondary | Cannulation-related outcomes | composite outcome of cannulation related complications | participants will be followed for the duration of ICU stay, an expected average of 4 days | |
Secondary | haemolysis related to the intervention | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | work of breathing | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | Time to cessation ECCO2R | Defined as from the commencement of ECCO2R to 6 hours following cessation of CO2 removal | participants will be followed for the duration of ICU stay, an expected average of 4 days | |
Secondary | Time to normalisation of pH | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | Hospital Length of stay | participants will be followed for the duration of hospital stay, an expected average of 10 days | ||
Secondary | Intubation rate | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | Incidence of tracheostomy | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | length of ICU stay | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | Tolerance of therapy | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | subjective dyspnoea | participants will be followed for the duration of ICU stay, an expected average of 4 days | ||
Secondary | nutrition | total caloric intake during interventional period | participants will be followed for the duration of ICU stay, an expected average of 4 days | |
Secondary | Mobilisation | mobilisation from bed during the study period | participants will be followed for the duration of ICU stay, an expected average of 4 days | |
Secondary | thrombotic complications | measurement of thrombotic complications in the patient related to the device | participants will be followed for the duration of ICU stay, an expected average of 4 days | |
Secondary | respiratory mechanics | participants will be followed for the duration of ICU stay, an expected average of 4 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|